1910 Genetics utilizes a multimodal AI platform that integrates computational data, wet lab proxy biological data, and wet lab ground truth biological data to enhance drug discovery for small and large molecules. The company focuses on delivering novel drug candidates for neurological, autoimmune diseases, and cancer while providing software solutions to pharmaceutical and technology partners.

DeepBiome Therapeutics is developing a drug discovery platform that utilizes advanced computational biology and machine learning to identify novel therapeutic compounds. This approach addresses the inefficiencies in traditional drug development processes, significantly reducing time and costs associated with bringing new drugs to market.

Enterin is developing ENT-01, a drug that targets the dysfunctional gut-brain axis in patients with neurodegenerative diseases, specifically Parkinson's Disease. Preclinical studies show that ENT-01 displaces α-synuclein aggregates and significantly improves quality of life by restoring normal signaling between the gut and brain.

Humanity develops a healthcare application that utilizes AI algorithms to monitor aging biomarkers, including sleep quality, activity levels, and nutritional habits, to calculate users' biological age. The app provides actionable insights to help users slow their aging process and reduce disease risk through personalized lifestyle adjustments.

IntelinAir provides aerial imagery analytics through its AGMRI platform, enabling farmers to monitor crop health, nitrogen levels, and other key production variables with high-resolution imagery and regular alerts. This technology allows for data-driven management decisions, improving yield potential and optimizing resource use throughout the growing season.

Sprout Pharmaceuticals develops pharmacological treatments specifically targeting female sexual dysfunction, utilizing evidence-based research to create effective therapeutic options. The company addresses the unmet medical needs of women experiencing sexual health issues, enhancing their quality of life through targeted interventions.

X-VAX is developing mucosal vaccines targeting pathogens like herpes, utilizing advanced adjuvant formulations to enhance immune response at mucosal surfaces. This approach aims to provide effective protection against infections that enter the body through mucosal membranes, addressing a significant gap in current vaccine offerings.